Summary List PlacementAbout a year ago, virtually every psychedelics company was focused on developing medical treatments that could be approved by regulators. In 2021, that's no longer the case. In just a short period of time, a whole network of psychedelics startups focused on tech, delivery, and distribution have risen up to lay the groundwork for what might become a $100 billion market. There are still biotech companies working through clinical trials and talking with regulators to get medications on the market, and those startups are as popular as well.